证券代码：688136 证券简称：科兴制药 公告编号：2023-057 科兴生物制药股份有限公司 关于控股股东及实际控制人自愿承诺特定期间不减持公司股份 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）于近日收到控股股东深圳 科益医药控股有限公司（以下简称"科益医药"）及实际控制人邓学勤先生共同 出具的《关于特定期间不减持公司股份的承诺函》，相关情况公告如下： 一、承诺事项 为促进证券市场稳定健康发展，基于对公司未来发展前景的信心及对公司价 值的认可，为促进公司持续、稳定、健康发展，本着对社会公众以及公司广大股 东负责的态度，控股股东科益医药及实际控制人邓学勤先生承诺：自 2023 年 12 月 14 日起 12 个月内（即自 2023 年 12 月 14 日至 2024 年 12 月 13 日），不减持 所持有的公司股份，包括承诺期间发生资本公积转增股本、派送股票红利、配股、 增发等产生的股份。 二、承诺主体持股情况 | 序号 | 股东名称 | 持股数量（股） | 持股 ...

证券代码：688136 证券简称：科兴制药 公告编号：2023-056 科兴生物制药股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上 市股数为 131,778,347 股。 本次股票上市流通总数为 131,778,347 股。 本次股票上市流通日期为 2023 年 12 月 14 日。 一、本次上市流通的限售股类型 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655 号）同意，公司首次公开发 行人民币普通股 49,675,300 股，并于 2020 年 12 月 14 日在上海证券交易所科创 板上市，发行后总股本为 198,700,650 股，其中有限售条件流通股为 157,791,528 股，无限售条件流通股为 40,909,122 股。 本次上市流通的限售股为公司首次公开发行部分限售股，共涉及限售股股东 1 名，为深圳科益医药控 ...

证券代码: 688136 证券简称：科兴制药 科兴生物制药股份有限公司投资者关系活动记录表 编号：2023-004 R特定对象调研 £分析师会议 □媒体采访 £业绩 投资者关系活动类别 说明会 □新闻发布会 □路演活动 £现场参观□其 他（请文字说明其他活动内容） 1、远策投资管理有限公司 参与单位名称及人员姓 2、平安资产管理有限责任公司 名 3、平安证券股份有限公司 2023年11月28日11：00-12：00 时间 2023年11月28日 17：00-18：00 深圳市南山区创益科技大厦B栋19楼 地点 腾讯会议 1、董事、总经理 赵彦轻先生 上市公司接待人员姓名 2、董秘兼财务总监 王小琴女士 3、IRD 段小霞女士 ...

证券代码：688136 证券简称：科兴制药 公告编号：2023-055 科兴生物制药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 11 月 22 日 下午 16:00-17:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 会议召开时间：2023 年 11 月 22 日(星期三) 下午 16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 15 日(星期三)至 11 月 21 日(星期 二)16: ...

Financial Performance - The company's revenue for Q3 2023 was ¥320,033,804.01, representing a year-over-year increase of 1.72%[5] - The net profit attributable to shareholders for Q3 2023 was a loss of ¥6,753,285.57, with a cumulative loss of ¥54,314,791.05 for the year-to-date[5] - The basic and diluted earnings per share for Q3 2023 were both -¥0.03, unchanged from the previous year[6] - The company's net profit for the first three quarters of 2023 was not explicitly stated, but the retained earnings decreased to ¥261,427,063.25 from ¥315,741,854.30 in the previous year, indicating a decline of approximately 17.2%[21] - The net profit for Q3 2023 was -58,128,050.99 RMB, compared to -57,964,481.50 RMB in Q3 2022, indicating a slight increase in losses year-over-year[24] - The total comprehensive income attributable to the parent company for Q3 2023 was -54,314,791.05 RMB, compared to -56,719,202.87 RMB in the same quarter last year[24] Research and Development - Research and development expenses for Q3 2023 totaled ¥91,715,895.27, an increase of 107.06% compared to the same period last year, accounting for 28.66% of revenue[6] - The company plans to continue accelerating its ongoing research projects, which have led to increased clinical trial costs[11] - The company completed the enrollment of all subjects for the Phase Ib clinical trial of the inhaled interferon α1b solution, aimed at treating respiratory syncytial virus (RSV) infections in children[15] - The company successfully completed the Phase I clinical trial of the polyethylene glycol-conjugated granulocyte colony-stimulating factor injection, showing good safety data, and is preparing for Phase III clinical trials[16] - The company received approval from the National Medical Products Administration to conduct clinical trials for the human growth hormone injection, with plans for Phase I trials underway[17] - The company is focusing on expanding its product pipeline, particularly in the oncology sector, to meet unmet clinical needs in Latin America and Southeast Asia[16] Assets and Liabilities - The total assets as of the end of Q3 2023 were ¥3,176,928,435.57, reflecting a slight increase of 0.58% from the end of the previous year[6] - The company's total assets as of the end of Q3 2023 amounted to ¥3,176,928,435.57, slightly up from ¥3,158,711,687.22 at the end of Q3 2022[21] - Total liabilities increased to ¥1,409,618,185.64 in Q3 2023, compared to ¥1,352,870,907.21 in Q3 2022, marking an increase of about 4.2%[20] - The total equity attributable to shareholders decreased to ¥1,761,152,857.11 in Q3 2023 from ¥1,808,369,403.23 in Q3 2022, a decline of about 2.6%[21] - The company has a long-term debt of approximately $779.23 million, indicating reliance on debt financing for growth[30] Cash Flow - The company reported a net cash flow from operating activities of -¥74,494,596.94 for the year-to-date[6] - Cash flow from operating activities for the first three quarters of 2023 was -74,494,596.94 RMB, compared to -104,887,138.13 RMB in the same period of 2022, showing a reduced cash outflow[26] - The net cash flow from financing activities in Q3 2023 was 45,491,733.57 RMB, a decrease from 318,157,273.68 RMB in Q3 2022[27] - The company incurred a total of 992,799,957.32 RMB in cash outflows from operating activities in the first three quarters of 2023, compared to 1,073,181,128.73 RMB in the previous year[26] Shareholder Information - As of September 30, 2023, the total number of common shareholders was 11,318[13] - The top ten shareholders include Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., holding 66.15% of shares[13] Strategic Initiatives - The company adjusted its sales strategy, resulting in a reduction of sales expenses by ¥59,500,600 compared to the previous year[11] - The company is actively communicating with the Center for Drug Evaluation (CDE) to expedite the registration of long-acting granulocyte colony-stimulating factor in emerging markets[16] - The company’s collaboration with partners in Egypt for the GMP audit of two products is expected to significantly boost overseas commercialization efforts[17]

科兴生物制药股份有限公司独立董事 关于第二届董事会第十次会议相关议案的 独立意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》《上 市公司治理准则》等要求以及《科兴生物制药股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，作为科兴生物制药股份有限公司（以下简称"公司"） 第二届董事会独立董事，我们参加了公司第二届董事会第十次会议，在认真审阅 并全面了解公司提供的相关资料的基础上，现就第二届董事会第十次会议相关议 案发表如下独立意见： 科兴生物制药股份有限公司 第二届董事会第十次会议 一、关于《关于补选非独立董事的议案》的独立意见 经审阅公司非独立董事候选人王小琴女士的个人履历等相关资料，我们认为， 王小琴女士具备《公司法》等有关法律法规以及《公司章程》规定的任职资格， 具备任职条件和履职能力，不存在《公司法》《证券法》、中国证券监督管理委员 会和上海证券交易所认定的不得担任上市公司董事的情形，也不存在被中国证券 监督管理委员会确定为市场禁入者并且尚未解除的情况。本次公司非独立董事候 选人的提名、审议及表决程序符合《公司法》等相关法律法规及《公司章程》的 规定，不存在损害股东特别是 ...

证券代码：688136 证券简称：科兴制药 公告编号：2023-054 （1）审计委员会 关于补选非独立董事并调整专门委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）董事会于2023年10月27日 召开第二届董事会第十次会议，审议通过了《关于补选非独立董事的议案》《关 于调整专门委员会委员的议案》，现将相关情况公告如下： 调整前：唐安（召集人）、曹红中、朱玉梅 一、补选董事情况 科兴生物制药股份有限公司 鉴于公司董事朱玉梅女士已辞去其担任的公司第二届董事会董事职务，为保 证公司董事会的规范运作，根据《公司法》及《公司章程》等相关规定，经公司 董事会提名委员会审核同意，公司于2023年10月27日召开第二届董事会第十次会 议审议通过了《关于补选非独立董事的议案》，公司董事会同意提名王小琴女士 为公司非独立董事候选人（简历详见附件），任期自公司股东大会审议通过之日 起至第二届监事会届满之日止。 公司独立董事对本事项发表了同意的独立意见，该事项尚需提交公司股东大 会审 ...

截至本公告披露日，朱玉梅女士未持有公司股份。根据《中华人民共和国公 司法》《公司章程》等有关规定，朱玉梅女士辞去职务自辞职申请送达公司董事 会时生效。朱玉梅女士辞职不会导致公司董事会低于法定最低人数，不会导致独 立董事人数少于董事会成员的三分之一，不会影响董事会和公司经营正常运作， 不会对本公司日常管理、生产经营产生影响。 朱玉梅女士在任职期间，恪尽职守、勤勉尽责，在公司规范治理和高质量发 展方面发挥了积极作用，公司及董事会对朱玉梅女士在任职期间为公司所做出的 贡献表示衷心感谢。 特此公告。 科兴生物制药股份有限公司董事会 证券代码：688136 证券简称：科兴制药 公告编号：2023-053 科兴生物制药股份有限公司 关于董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）董事会于近日收到董事朱 玉梅女士的书面辞职报告，朱玉梅女士因个人原因辞去公司第二届董事会董事职 务，同时一并辞去第二届董事会审计委员会、提名委员会、薪酬与考核委员会委 员职务。朱玉梅女士辞任后，将 ...

中信建投证券股份有限公司 关于科兴生物制药股份有限公司 2023年半年度持续督导跟踪报告 | 保荐机构名称：中信建投证券股份有 | 被保荐公司名称：科兴生物制药股份 | | --- | --- | | 限公司 | 有限公司 | | 保荐代表人姓名：徐新岳 | 联系方式：0755-23953869 | | | 联系地址：深圳市福田区鹏程一路广 | | | 电金融中心大厦35层 | | 保荐代表人姓名：张星明 | 联系方式：0755-23953869 | | | 联系地址：深圳市福田区鹏程一路广 | | | 电金融中心大厦35层 | 2020年12月14日，科兴生物制药股份有限公司（简称"公司"或"科兴制药"） 首次公开发行股票并在科创板上市。中信建投证券股份有限公司（简称"中信建 投证券"、"保荐机构"）担任本次公开发行股票的保荐机构。根据《证券发行 上市保荐业务管理办法》等相关规定，由中信建投证券完成持续督导工作。根据 《证券发行上市保荐业务管理办法》和《上海证券交易所上市公司自律监管指引 第11号——持续督导》等相关规定，中信建投证券出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | ...

Financial Performance - The company's basic earnings per share for the first half of 2023 was -0.24 yuan, a decrease of 2,493.63% compared to the same period last year[20]. - The diluted earnings per share for the same period was also -0.24 yuan, reflecting the same significant decline[20]. - The company's net profit attributable to shareholders decreased significantly due to increased R&D investment, with R&D expenses rising by 44.93 million yuan compared to the previous year[20]. - The net profit attributable to shareholders of the listed company was -¥47,561,505.48, a significant decrease of 1,741.43% from ¥2,897,571.63 in the previous year[21]. - The net cash flow from operating activities decreased by 157.71% to -¥87,139,193.83, compared to -¥33,813,425.74 in the same period last year[21]. - The company's operating revenue for the first half of 2023 was ¥648,964,150.78, representing a year-on-year increase of 3.11% compared to ¥629,379,018.44 in the same period last year[21]. - The weighted average return on net assets was -2.66%, a decrease of 2.81 percentage points year-on-year[20]. - The weighted average return on net assets, excluding non-recurring gains and losses, was -4.01%, down by 4.19 percentage points compared to the same period last year[20]. Research and Development - The proportion of R&D investment to operating income increased to 30.01%, up by 17.40 percentage points from the previous year[20]. - The report period was marked by a significant increase in R&D investment as part of the company's strategic focus[20]. - R&D investment totaled approximately ¥194.72 million in the reporting period, a significant increase of 145.28% compared to ¥79.39 million in the same period last year[44]. - Clinical and outsourcing expenses increased by ¥105.57 million, representing a growth of 592.07% year-on-year, due to the acceleration of ongoing projects[42]. - The company has committed to accelerating ongoing research projects and enhancing R&D activities[20]. - The company has established a comprehensive and controllable R&D, procurement, production, and marketing system, focusing on independent and collaborative R&D[33]. - The company has restructured its technology platforms into three main areas: recombinant protein drug development, antibody drug development, and nucleic acid drug development, enhancing its competitive edge[39]. - The company has a total of 49 patents as of June 30, 2023, including 36 invention patents and 13 design patents, with 3 new invention patents obtained in the first half of 2023[40]. Market Position and Products - The market share of the company's main product, "赛若金®" (recombinant human interferon), reached 41.91%, ranking first in the domestic market for short-acting injections[28]. - "Yipuding®" (human erythropoietin) ranked second in the domestic market with a market share of 15.93%, showing an increase in its market presence[37]. - "Baitexi®" (short-acting human granulocyte colony-stimulating factor) improved its ranking from seventh to fifth, achieving a market share of 6.45%[37]. - The company is focusing on the development of new protein drugs, antibodies, and nucleic acid drugs, with ongoing clinical trials for several projects, including PEGylated recombinant human granulocyte colony-stimulating factor injection[28]. - The company has introduced overseas commercialization rights for two major breast cancer drugs, trastuzumab and neratinib, in collaboration with partners[27]. - The company has established a marketing network covering approximately 18,000 medical institutions, including nearly 7,000 hospitals and over 3,500 pharmacies[28]. - The company exports products to approximately 40 countries, including Brazil, the Philippines, and Indonesia, enhancing its international market competitiveness[35]. Financial Position - The total assets at the end of the reporting period were ¥3,230,572,668.00, reflecting a year-on-year increase of 2.28%[21]. - The net assets attributable to shareholders decreased by 2.32% to ¥1,766,347,086.68 compared to the end of the previous year[21]. - The company's total liabilities increased to CNY 1,456,615,944.45 from CNY 1,352,870,907.21, reflecting an increase of approximately 7.68%[200]. - The total equity attributable to shareholders decreased to CNY 1,766,347,086.68 from CNY 1,808,369,403.23, a decline of about 2.33%[200]. - Cash and cash equivalents decreased by 31.05% to CNY 541,515,834.34 from CNY 785,382,355.26 year-over-year, primarily due to the purchase of financial products that had not yet matured[86]. - Accounts receivable increased by 81.40% to CNY 42,747,758.36 from CNY 23,566,086.42 year-over-year, mainly due to an increase in bank bills with general acceptance credit ratings[86]. Environmental Responsibility - The company invested 1.5721 million CNY in environmental protection during the reporting period[104]. - The total COD emissions from the company were 0.689 tons, with a maximum allowable limit of 7.702 tons, indicating no exceedance of the standard[106]. - The company has achieved zero wastewater discharge through optimization of wastewater treatment methods[106]. - The company operates wastewater treatment facilities with a design capacity of 400 m³/d and 350 m³/d, both functioning normally[107]. - The company has established a comprehensive environmental management system and conducts regular environmental inspections and training[113]. - The company actively responds to national carbon neutrality goals by implementing low-carbon and energy-saving measures in its operations[114]. Governance and Compliance - The company has maintained a consistent approach to governance and oversight, ensuring compliance with relevant laws and regulations[96]. - The company has not faced any environmental protection administrative penalties during the reporting period[112]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[159]. - The company has not issued any non-standard audit opinions in the previous annual report[159]. - The company has established a mechanism for board members and senior management to be accountable for compensation in case of misleading statements[144]. Shareholder Commitments - The controlling shareholder, Keyi Holdings, commits to not transferring or entrusting the management of shares held before the IPO for 36 months post-listing[119]. - The actual controller, Deng Xueqin, agrees to a similar 36-month lock-up period for shares held prior to the IPO[120]. - All directors and senior management will not transfer shares held before the IPO for 12 months post-listing[122]. - Core technical personnel are restricted from transferring shares for 12 months post-listing and for 6 months after leaving the company[124]. - The company commits to repurchase shares if fraud in the issuance process is confirmed by regulatory authorities[134].